Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to observe and evaluate the efficacy and safety of postoperative adjuvant treatment of pembrolizumab in patients with thoracic esophageal squamous cell carcinoma (ESCC) who have not received neoadjuvant therapy before undergoing R0 resection, and have positive postoperative lymph nodes.


Clinical Trial Description

For patients with thoracic esophageal squamous cell carcinoma (ESCC) who have undergone R0 resection, have not received neoadjuvant therapy, and have positive postoperative lymph nodes, there is no international consensus on whether postoperative adjuvant therapy is required. The JCOG9204 study reported that for patients with ESCC with positive lymph nodes after R0 resection, postoperative adjuvant chemotherapy can improve the disease-free survival (DFS) of the ESCC patients. However, due to the adverse effects of chemotherapy, patients are often difficult to tolerate. We designed a single-arm, open-label, phase II trial of pembrolizumab for adjuvant treatment after R0 resection of thoracic ESCC Patients with lymph node positive. The purpose of this study is to observe and evaluate the efficacy and safety. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04863079
Study type Interventional
Source Tianjin Medical University Cancer Institute and Hospital
Contact Hongjing Jiang, MD, PhD
Phone +8618622221069
Email [email protected]
Status Recruiting
Phase Phase 2
Start date May 1, 2021
Completion date April 30, 2024

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04333004 - Analysis of Gut Microbiota in Patients With Brain Metastasis of Non-small Cell Lung Cancer Treated by Pembrolizumab Combined With Chemotherapy Phase 1/Phase 2
Recruiting NCT04393883 - A Study With Pembrolizumab for Non-small Cell Lung Cancer (NSCLC) N/A
Recruiting NCT04813523 - Pembrolizumab Plus Neoadjuvant Chemotherapy for Locally Advanced EGJ Adenocarcinoma Phase 2